Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Multi-center, Randomized, subject-and Investigator Blinded, Placebo-controlled, Active Comparator, Parallel-group Proof of Concept Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Patients With Treatment-resistant Depression

To see complete record on, please visit this link

Id: NCT03756129

Organisation Name: Novartis

Overal Status: Completed

Start Date: February 8, 2019

Last Update: October 8, 2021

Lead Sponsor: Novartis Pharmaceuticals

Brief Summary: This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain). The MIJ821 was administered via infusion on a weekly or bi-weekly basis. The efficacy was measured after 24 hours using a specific golden standard scale, the Montgomery-Asberg Depression Rating Scale. The study duration was 6 weeks of treatment plus 1 month of follow up period.

  • Depressive Disorder, Treatment-Resistant

Total execution time in seconds: 0.38672304153442